Frequency and clinical importance of anti-Tg auto-antibodies (ATG)

Journal of the College of Physicians and Surgeons Pakistan

Volumn 13, Issue 9, 2003, Pages 504-506

  Adil, Allah Rakha ^a,e   Jafri, Rafaqat A ^b   Waqar, Amin ^c   Abbasi, Siraj A ^a   Matiul Haq, A ^d   Asghar, A H ^d   Jilani, Asif ^a   Naz, Irum ^a  

^a Larkana Inst Nucl Med/Radiother   (Pakistan)

^b PAKISTAN ATOMIC ENERGY COMMISSION   (Pakistan)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

^d University Campus   (Pakistan)

^e NISHTAR MEDICAL COLLEGE   (Pakistan)

Author keywords

Anti Tg autoantibodies; ATG; DTC follow up; Tg

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; LASER SURGERY; MALE; PAKISTAN; SUBTOTAL THYROIDECTOMY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 0142042782     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Feldt-Rasmussen U. Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin and thyrotropin receptor. Clin Chem 1996;42:160-3.
2. Paindakhel SMK. Goiter in north of Kalam. J Pak Med Assoc 1981; 31:178.
3. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age and multinodularity. Am J Med 1992; 93: 363-9.
4. Mariotti S, Cupini C, Giani C, Lari R, Rolleri E, Falco A, et al Evaluation of a solid phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody. Clin Chim Acta 1982;123:347-5.
5. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
6. Van Herle AJ, Uller RP. Elevated serum Tg: a marker of metastases in DTC. J Clin Invest 1975;56:272-7.
7. Black EG, Sheppard MC, Hoffenberg R. Serial serum Tg measurements in the management of DTC. Clin Endocrinol 1987;27:115-20.
8. Schlumberger M, Tubiana M, DeVathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-67.
9. Schneider AB, Pervos R. Radioimmunoassay of human Tg: effect of ATG. J Clin Endocrinol Metab. 1978;47:126-37.
10. Schaadt B, Feldt- Rasmussen U, Rasmussen B, Torring H, Foder B, Jorgensen K, et al. Assessment of the influence of Tg autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma. Thyroid 1995;5:165-70.
11. Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P, et al. Low levels of serum Tg after withdrawal of thyroid suppression therapy in the follow-up of differentiated thyroid carcinoma. Eur J Nucl Med 1990;16:35-38.
12. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.
13. Kumar A, Shah DH, Shrihari U, Dandker SR, Vijayan U, Sharma SM. Significance of Tg autoantibodies in differentiated thyroid carcinoma. Thyroid 1994;4:199-202.
14. Spencer CA, Takeuchi M, Kazarsyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996;42:164-73.